FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review

Cancer Imaging

Review

Ayça Arçay Öztürk¹  Patrick Flamen¹ 

[1] Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium;

关键词: Fibroblast activation protein;    Cancer-associated fibroblasts;    FAPI;    PET;    Gastrointestinal oncology;    FDG PET/CT;    FAPI PET/CT;    Gastric cancer;    Colorectal cancer;   

DOI  :  10.1186/s40644-023-00598-z

 received in 2023-03-29, accepted in 2023-08-07,  发布年份 2023

来源: Springer

【 摘 要 】

F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) plays a crucial role in tumour diagnosis, staging, and therapy response evaluation of various cancer types and has been a standard imaging modality used in clinical oncology practice for many years. However, it has certain limitations in evaluating some particular gastrointestinal cancer types due to low FDG-avidity or interphering physiological background activity. Fibroblast activation protein (FAP), a protein of the tumour microenvironment, is overexpressed in a wide range of cancers which makes it an attractive target for both tumour imaging and therapy. Recently, FAP-targeted radiopharmaceuticals are widely used in clinical research and achieved great results in tumour imaging. Considering the limitations of FDG PET/CT and the lack of physiological FAP-targeted tracer uptake in liver and intestinal loops, gastrointestinal cancers are among the most promising indications of FAP-targeted imaging. Herein, we present a comprehensive review of FAP-targeted imaging in gastrointestinal cancers in order to clarify the current and potential future role of this class of molecules in gastrointestinal oncology.

【 授权许可】

CC BY   
© International Cancer Imaging Society (ICIS) 2023

【 图 表 】

Fig. 3

Fig. 3

Fig. 6

13690_2023_1147_Article_IEq16.gif